BCBP vs JPM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
BCBP exhibits weak financial health with a Piotroski F-Score of 4/9, indicating borderline stability, and lacks an Altman Z-Score to confirm safety from distress. The stock trades at a significant premium to its Graham Number of $4.79, currently priced at $7.86, despite deteriorating fundamentals including negative earnings and revenue growth. Profitability metrics like ROE (0.86%) and ROA (0.08%) are extremely weak, while the dividend is unsustainable with a payout ratio exceeding 1000%. Although analysts recommend a 'buy' with a $9.50 target, the company's track record of earnings misses and declining performance raises serious concerns.
JPM shows bullish fundamentals based on deterministic rules. Financial strength is weak (F-Score 2/9). Key strengths include strong valuation and growth metrics. Price trades at a 109.8% premium to fair value estimate ($140.21), limiting near-term upside from a valuation perspective.
Compare Another Pair
Related Comparisons
BCBP vs JPM: Head-to-Head Comparison
This page compares BCB Bancorp, Inc. (BCBP) and JPMorgan Chase & Co. (JPM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.